Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Not a peripheral story

    Beyond peripheral autoimmunity in Type I diabetes

    By looking in pancreatic islets rather than blood, a UMass team has uncovered a trove of new antigens that drive Type I diabetes.

    Published on 12/1/2016
  • Figure: A lethal halo

    Not a peripheral story Targets & Mechanisms A lethal halo In a Nature Medicine study published in October, researchers from the University of Massachusetts Medical School profiled islet-infiltrating T cells from …

    Published on 12/1/2016
  • Figure: Commercialization gap

    China's dysfunctional patent flood Strategy Commercialization gap Although Chinese universities file many more patents each year than academic institutes in the U.S. and Europe, they lag behind when it comes to …

    Published on 11/17/2016
  • Figure: No contest

    China's dysfunctional patent flood Strategy No contest Chinese universities beat U.S. and U.K. universities by an order of magnitude when it comes to patenting their technologies. The chart shows the numbers of …

    Published on 11/17/2016
  • China's dysfunctional patent flood

    How poor patents hinder tech transfer in China

    A mountain of poor quality patents is hampering commercialization of Chinese science. The question is whether government reforms will change the landscape.

    Published on 11/17/2016
  • Chemistry beyond candidates

    AZN chemists tackle common problems in compound innovation

    AstraZeneca is broadcasting its stepped-up chemistry focus with a tetrad of publications on innovative molecule design.

    Published on 11/10/2016
  • Figure: Chemistry quartet

    Chemistry beyond candidates Tools & Techniques Chemistry quartet AstraZeneca plc (LSE:AZN; NYSE:AZN) published a series of four studies addressing key stumbling blocks in medicinal chemistry that the company …

    Published on 11/10/2016
  • Box: Going, going, gone

    The next (re)generation Strategy Going, going, gone The failure of first-wave regenerative medicine companies still looms large for industry and investors. Three high-profile busts in the last three years could be …

    Published on 11/3/2016
  • Figure: Regenerative Venture

    The next (re)generation Strategy Regenerative Venture In the last decade, VC investment in regenerative medicine companies has been highly variable, but the last three years have seen a big uptick in private …

    Published on 11/3/2016
  • The next (re)generation

    Why investors both want and worry about regenerative medicine

    Despite scientific progress in regenerative medicine, stakeholders fear technical challenges and company missteps could turn off both investors and regulators.

    Published on 11/3/2016
  • Cancer's Phoenix

    A safer IL-2-based immunotherapy without compromised efficacy

    Courier Therapeutics may have solved the longstanding problem of how to avoid the lethal side effects of IL-2 cancer immunotherapy without compromising efficacy.

    Published on 10/27/2016
  • Figure: Aim intermediate

    Cancer's Phoenix Targets & Mechanisms Aim intermediate To avoid dose-limiting toxicities associated with recombinant IL-2, researchers at Washington University in St. Louis have created a fusion protein that …

    Published on 10/27/2016
  • Figure: Check This Out

    Cancer's Phoenix Targets & Mechanisms Check This Out Therapeutic response rates for metastatic renal cell carcinoma (RCC) patients treated with high-dose IL-2 or anti-PD1 antibody therapies, broken down by complete…

    Published on 10/27/2016
  • Table: BioCentury Product Profile

    Cancer's Phoenix Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A fusion protein comprising a mutant form of IL-2 with diminished CD25 binding, linked to the …

    Published on 10/27/2016
  • Table: Everything old is new again

    Cancer's Phoenix Targets & Mechanisms Everything old is new again IL-2-based therapeutics in clinical and preclinical development. At least seven products containing a form of IL-2 are in clinical development, and …

    Published on 10/27/2016
  • Figure: Chaperoned pairing

    Chaperoning the DJ Product R&D Chaperoned pairing Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) is developing pharmacological chaperones to prevent protein misfolding in neurological diseases. The company's lead …

    Published on 10/20/2016
  • Table: BioCentury Product Profile

    Chaperoning the DJ Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that stabilizes the dimeric form of DJ-1, a chaperone protein and oxidative stress sensor…

    Published on 10/20/2016
  • Chaperoning the DJ

    How Cantabio is using chaperones to rein in multiple PD pathways

    By stabilizing the chaperone and oxidative stress sensor DJ-1, Cantabio is aiming to block multiple PD pathways with a single compound.

    Published on 10/20/2016
  • Exosomes in the zone

    Academia and industry agree that exosomes are ready for prime time

    The rise in exosome knowledge has the field poised to deliver a possibly transformational technology for diagnostics, with therapeutic applications on their trail.

    Published on 10/13/2016
  • Figure: Exosome publications

    Exosomes in the zone Strategy Exosome publications The publication of exosome-related papers has risen by an order of magnitude since 2006, and the totals for 2016 through Oct. 11 have already surpassed 2015 totals…

    Published on 10/13/2016
  • Table: Companies chasing exosomes

    Exosomes in the zone Strategy Companies chasing exosomes At least 12 companies are pursuing therapeutics or diagnostics that utilize exosomes, including at least seven whose primary focus is exosome-based …

    Published on 10/13/2016
  • Table: Exosomes in fashion

    Exosomes in the zone Strategy Exosomes in fashion At least three new companies have been founded in the last two years based on exosome technology, and a fourth company, founded earlier, raised early stage …

    Published on 10/13/2016
  • Local sensitivity

    How Cell Design rewires T cell therapies for local action in multiple diseases

    Cell Design is rewiring cells for local delivery of therapeutics, using synthetic receptors that respond to endogenous cues in the tissue or tumor microenvironment.

    Published on 10/6/2016
  • Box: CAR factories

    Local sensitivity Product R&D CAR factories While Cell Design Labs Inc. created a system for cell therapies to produce proteins in vivo in response to endogenous cues, a team from Memorial Sloan Kettering Cancer …

    Published on 10/6/2016
  • Box: Taking it up a notch

    Local sensitivity Product R&D Taking it up a notch In a study in Cell, a University of California San Francisco team showed how its synthetic Notch (synNotch) technology turns T cells into "smart" agents that …

    Published on 10/6/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993